Company news

NovoCure Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update

January 8, 2023

Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

January 4, 2023

Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference

December 26, 2022

Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

November 28, 2022

Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference

November 22, 2022

Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting

November 16, 2022

Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada

November 14, 2022

Novocure Secures CE Mark for New Array

November 10, 2022

Novocure Reports Third Quarter 2022 Financial Results

October 26, 2022

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

October 20, 2022

Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy

October 19, 2022

Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology

October 19, 2022

Novocure to Report Third Quarter 2022 Financial Results

October 2, 2022

Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business

September 20, 2022

Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility

August 9, 2022

Novocure Reports Second Quarter 2022 Financial Results

July 27, 2022

Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

July 26, 2022

Novocure to Report Second Quarter 2022 Financial Results

June 30, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

June 20, 2022

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

June 2, 2022

Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma

May 25, 2022

Novocure Reports First Quarter 2022 Financial Results

April 27, 2022

Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu

April 18, 2022

Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields

April 7, 2022

Novocure to Report First Quarter 2022 Financial Results

March 31, 2022

Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial

March 23, 2022

Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer

March 22, 2022

Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation

February 27, 2022

Novocure’s General Counsel Resigns After 10 Years of Service

February 23, 2022

Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

February 23, 2022

New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response

February 23, 2022

Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update

January 9, 2022

Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire

December 6, 2021

Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

December 5, 2021

Novocure to Participate in Two Upcoming Investor Conferences

November 22, 2021

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

November 21, 2021

Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting

November 14, 2021

2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma

November 14, 2021

Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update

October 27, 2021

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer

October 27, 2021

Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting

October 20, 2021

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

October 3, 2021

Novocure to Report Third Quarter 2021 Financial Results

October 3, 2021

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

October 3, 2021

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

September 13, 2021

FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer

September 8, 2021

Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

September 1, 2021

Novocure Appoints Bill Burke as Chief Human Resources Officer

August 31, 2021

Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update

July 28, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 25 decks. Every deck is listed under its year.